We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arana Therap. | LSE:AAHX | London | Ordinary Share | AU000000AAH8 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 50.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:0163M Arana Therapeutics Limited 17 January 2008 For Immediate Release 17 January 2008 ARANA THERAPEUTICS LTD Grant of Shares to Director Under Performance Share Plan Arana Therapeutics Ltd, (LSE: AAHx ASX:AAH) ("Arana" or the "Company"), the Australian biopharmaceutical company, formed through the merger of Peptech and EvoGenix in August 2007. The Company uses superior technology to develop next generation drugs that will improve the lives of patients with inflammatory diseases and cancer. The Company announced today that Dr Phil Jennings, a director of the Company, has been granted 31,694 ordinary shares of no par value in the capital of the Company at a price of nil per share under the Performance Share Plan as approved by Shareholders at the Annual General Meeting held in February 2005. +----------+---------+---------+---------+-------------+-----------------+ |Director |Direct or|No. of |Date |Consideration|Subsequent | | |Indirect |Shares |Granted |(A$) |beneficial | | |Interest |Granted | | |holding | +----------+---------+---------+---------+-------------+-----------------+ |Phil |Direct |31,694 |15 |Nil |6,135 (indirect | |Jennings | | |January | |interest) | | | | |2008 | | | | | | | | | | | | | | | |67,317 (direct | | | | | | |interest) | | | | | | | | | | | | | | | +----------+---------+---------+---------+-------------+-----------------+ | | | | | | | +----------+---------+---------+---------+-------------+-----------------+ As a consequence of this grant, the total number of shares of Arana held by Dr Jennings represents less than 0.1% of the issued share capital. For further information, please contact: Arana Therapeutics Ltd Dr John Chiplin, Chief Executive Officer +61 (0)2 8061 9900 Niall Henderson, Chief Financial Officer +61 (0)2 8061 9900 Buchanan Communications Lisa Baderoon (lisab@buchanan.uk.com) +44 (0)20 7466 5000 Rebecca Skye Dietrich / Catherine Breen Nomura Code Securities Charles Walker +44 (0)20 7776 1206 This information is provided by RNS The company news service from the London Stock Exchange END RDSDGGMMDNZGRZM
1 Year Arana Therap. Chart |
1 Month Arana Therap. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions